⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474340 | 0.74 | NR4A1 (0.44) | — | |
| SCHEMBL769225 | 0.72 | — | — | |
| SCHEMBL512928 | 0.71 | NOTUM (0.42) | — | |
| SCHEMBL5324357 | 0.71 | ESR1 (0.43) | — | |
| SCHEMBL5465667 | 0.68 | MAPT (0.52) | — | |
| SCHEMBL314750 | 0.67 | EGFR (0.47) | — | |
| SCHEMBL769224 | 0.67 | ALDH1A1 (0.43) | — | |
| SCHEMBL9454247 | 0.65 | PTPRS (0.32) | — | |
| SCHEMBL15515389 | 0.65 | — | — | |
| SCHEMBL27657477 | 0.64 | CYP2A6 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102423-A1 | Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20040067915-A1 | Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone | G.D. SEARLE & CO. (US) | 2004-04-08 | — | — | US | claimed |
| US-20040053903-A1 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist | G.D. SEARLE & CO. | 2004-03-18 | — | — | US | claimed |
| US-6653306-B1 | Circulatory disorders | G.D. SEARLE & CO. | 2003-11-25 | — | — | US | claimed |
| EP-0831911-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0831910-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040255-A2 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION THERAPY OF AN ANGIOTENSIN II ANTAGONIST AND AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040257-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040256-A1 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION OF AN ANGIOTENSIN II ANTAGONIST AND SPIRONOLACTONE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| CN-111978317-A | Imidazopyridine MNK1/MNK2 kinase inhibitor and preparation method and application thereof | 上海道熵生物科技有限公司 | 2020-11-24 | — | — | CN | disclosed |
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-15 | — | — | US | disclosed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | disclosed |
| WO-1996040255-A2 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION THERAPY OF AN ANGIOTENSIN II ANTAGONIST AND AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040256-A1 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION OF AN ANGIOTENSIN II ANTAGONIST AND SPIRONOLACTONE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5215983-A | Useful for treatment of infectious diseases in a human as well as animal | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0424832-A2 | Carbapenem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |